VJHemOnc is committed to improving our service to you

ASCO 2016 | Targeted therapies for CLL: new data and unanswered questions

VJHemOnc is committed to improving our service to you

Jennifer Brown

Jennifer Brown, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA gives an overview of her talk on targeted therapy in chronic lymphocytic leukemia (CLL) held at the American Society of Oncology (ASCO) 2016 Annual Meeting in Chicago, IL. Dr Brown adresses unanswered questions such as how to salvage patients who relapse on the BTK inhibitor ibrutinib and how to optimize the management of toxicities some patients experience. Dr Brown further discusses the issues around the trial of the PI-3 kinase inhibitor idelalisib, in particular infections in the setting of neutropenia.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter